NLRP3 and inflammatory bowel disease: Meanwhile, nanoparticle delivery of miR-223 mimetics can constrain the level of NLRP3 activation, provides an early break, limiting cytokine-mediated immune disequilibrium, and attenuate experimental IBD (4).